Coherus Q2 net revenue $58.7M (+81% QoQ); CIMERLI sales quadruple to $26.7M

Coherus Oncology, Inc.

2023-Q2 EPS reported -$1.42 revenue$91,152,000

Net revenue $58.7M, up 81% from prior quarter; UDENYCA $31.7M, CIMERLI $26.7M.
Net loss $42.9M ($0.49 diluted EPS); non-GAAP net loss $32.8M ($0.38).
Launched UDENYCA autoinjector in May, YUSIMRY (Humira biosimilar) in July.
Planned merger with Surface Oncology expected to close after Sep 7 shareholder meeting.
FDA inspections for toripalimab ongoing; potential approval and launch H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Coherus Oncology, Inc. reported the second quarter ended June 30, 2023 results: revenue $58.7 million.

Period: the second quarter ended June 30, 2023
Revenue: $58.7 million
Result: reported results

Exact text from the filing

Net revenue was $58.7 million during the three months ended June 30, 2023

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-012903

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.